Targeting CCR2+ Macrophages to Enhance Pancreatic Cancer Treatment | Innovative Strategy for Reducing Tumor Recurrence Following Irreversible Electroporation

In this episode of SciBud, host Maple takes you on an illuminating journey into recent breakthroughs in pancreatic cancer treatment, focusing on a study that unveils a promising strategy against pancreatic ductal adenocarcinoma (PDAC), known for its aggressive nature and resistance to conventional therapies. Discover how researchers have harnessed a technique called irreversible electroporation (IRE) and targeted troublesome CCR2+ macrophages—cells that contribute to tumor evasion of the immune system—to enhance treatment efficacy. By employing a novel delivery system that combines a CCR2 inhibitor with the chemotherapy drug gemcitabine, scientists demonstrated a significant reduction in tumor recurrence and improved immune response in preclinical models. Maple breaks down these complex findings, discusses their implications for future therapies, and emphasizes the importance of innovative approaches in the fight against cancer. Join us for this engaging exploration of cutting-edge science that could shape the future of pancreatic cancer care! Link to episode page with article citation: www.scibud.media/podcast/season/2025/episode/98